Beta-blockers in heart failure

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Beta-blocker therapy for heart failure has gained popularity as a result of recent growing evidence that this group of drugs can reverse or slow the progressive left ventricular dilation that characterizes heart failure. Although the mechanism of this favourable effect on remodelling remains unclear, the present evidence indicates that at least a portion of the long-term benefit of these drugs is mediated through their β-blocking action. A direct effect on myocyte and interstitial growth may be a key factor in their ability to inhibit the remodelling process. The growing database will eventually raise the possibility that all patients with left ventricular dilation should take one of these drugs. A better understanding of differing mechanisms in individual patients would ideally provide selectivity in the therapeutic approach.

Original languageEnglish (US)
Pages (from-to)F52-F55
JournalEuropean Heart Journal
Volume19
Issue numberSUPPL. F
StatePublished - Jun 22 1998

Fingerprint

Heart Failure
Dilatation
Pharmaceutical Preparations
Muscle Cells
Databases
Therapeutics
Growth

Keywords

  • ACE inhibitors
  • Beta-blockers
  • Left ventricular remodelling
  • Morbidity
  • Mortality

Cite this

Beta-blockers in heart failure. / Cohn, J. N.

In: European Heart Journal, Vol. 19, No. SUPPL. F, 22.06.1998, p. F52-F55.

Research output: Contribution to journalArticle

Cohn, JN 1998, 'Beta-blockers in heart failure', European Heart Journal, vol. 19, no. SUPPL. F, pp. F52-F55.
Cohn, J. N. / Beta-blockers in heart failure. In: European Heart Journal. 1998 ; Vol. 19, No. SUPPL. F. pp. F52-F55.
@article{9ef21c4c9b784dfa9245a456a64fcc22,
title = "Beta-blockers in heart failure",
abstract = "Beta-blocker therapy for heart failure has gained popularity as a result of recent growing evidence that this group of drugs can reverse or slow the progressive left ventricular dilation that characterizes heart failure. Although the mechanism of this favourable effect on remodelling remains unclear, the present evidence indicates that at least a portion of the long-term benefit of these drugs is mediated through their β-blocking action. A direct effect on myocyte and interstitial growth may be a key factor in their ability to inhibit the remodelling process. The growing database will eventually raise the possibility that all patients with left ventricular dilation should take one of these drugs. A better understanding of differing mechanisms in individual patients would ideally provide selectivity in the therapeutic approach.",
keywords = "ACE inhibitors, Beta-blockers, Left ventricular remodelling, Morbidity, Mortality",
author = "Cohn, {J. N.}",
year = "1998",
month = "6",
day = "22",
language = "English (US)",
volume = "19",
pages = "F52--F55",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "SUPPL. F",

}

TY - JOUR

T1 - Beta-blockers in heart failure

AU - Cohn, J. N.

PY - 1998/6/22

Y1 - 1998/6/22

N2 - Beta-blocker therapy for heart failure has gained popularity as a result of recent growing evidence that this group of drugs can reverse or slow the progressive left ventricular dilation that characterizes heart failure. Although the mechanism of this favourable effect on remodelling remains unclear, the present evidence indicates that at least a portion of the long-term benefit of these drugs is mediated through their β-blocking action. A direct effect on myocyte and interstitial growth may be a key factor in their ability to inhibit the remodelling process. The growing database will eventually raise the possibility that all patients with left ventricular dilation should take one of these drugs. A better understanding of differing mechanisms in individual patients would ideally provide selectivity in the therapeutic approach.

AB - Beta-blocker therapy for heart failure has gained popularity as a result of recent growing evidence that this group of drugs can reverse or slow the progressive left ventricular dilation that characterizes heart failure. Although the mechanism of this favourable effect on remodelling remains unclear, the present evidence indicates that at least a portion of the long-term benefit of these drugs is mediated through their β-blocking action. A direct effect on myocyte and interstitial growth may be a key factor in their ability to inhibit the remodelling process. The growing database will eventually raise the possibility that all patients with left ventricular dilation should take one of these drugs. A better understanding of differing mechanisms in individual patients would ideally provide selectivity in the therapeutic approach.

KW - ACE inhibitors

KW - Beta-blockers

KW - Left ventricular remodelling

KW - Morbidity

KW - Mortality

UR - http://www.scopus.com/inward/record.url?scp=0031802478&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031802478&partnerID=8YFLogxK

M3 - Article

C2 - 9651736

AN - SCOPUS:0031802478

VL - 19

SP - F52-F55

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - SUPPL. F

ER -